Strata Critical Medical (SRTA) 주식 개요
는 미국 의료 업계에 시간이 생명인 물류 및 의료 서비스를 제공합니다. 자세히 보기
SRTA Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strata Critical Medical, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$5.88 |
| 52주 최고가 | US$6.50 |
| 52주 최저가 | US$3.57 |
| 베타 | 2.2 |
| 1개월 변동 | 1.38% |
| 3개월 변동 | 41.01% |
| 1년 변동 | 56.80% |
| 3년 변동 | 66.10% |
| 5년 변동 | -47.17% |
| IPO 이후 변동 | -39.69% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 07
SRTA: Fresh Bullish Coverage And 2026 Guidance Will Support Future Upside
Narrative Update: Strata Critical Medical The analyst price target for Strata Critical Medical has moved from $11.25 to $11.50. Analysts point to fresh bullish coverage and updated assumptions on revenue growth, profit margins and future P/E multiples as key drivers of the change.
내러티브 업데이트 • May 24
SRTA: Bullish Coverage And 2026 Revenue Guidance May Support Future Upside
Strata Critical Medical's updated analyst price target has moved to $9.13 from $8.81, as analysts point to revised assumptions around growth, margins, and future P/E expectations following recent bullish coverage and a $0.25 increase in one firm's target. Analyst Commentary Recent Street research on Strata Critical Medical has leaned positive, with several firms initiating bullish coverage and one lifting its price target by $0.25.Recent updates
내러티브 업데이트 • Jun 07
SRTA: Fresh Bullish Coverage And 2026 Guidance Will Support Future Upside
Narrative Update: Strata Critical Medical The analyst price target for Strata Critical Medical has moved from $11.25 to $11.50. Analysts point to fresh bullish coverage and updated assumptions on revenue growth, profit margins and future P/E multiples as key drivers of the change.내러티브 업데이트 • May 24
SRTA: Bullish Coverage And 2026 Revenue Guidance May Support Future Upside
Strata Critical Medical's updated analyst price target has moved to $9.13 from $8.81, as analysts point to revised assumptions around growth, margins, and future P/E expectations following recent bullish coverage and a $0.25 increase in one firm's target. Analyst Commentary Recent Street research on Strata Critical Medical has leaned positive, with several firms initiating bullish coverage and one lifting its price target by $0.25.분석 기사 • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...
내러티브 업데이트 • May 08
SRTA: Higher 2026 Guidance And Mixed Risk Signals Will Support Future Upside
Analysts have nudged their average price target for Strata Critical Medical higher by $0.25, reflecting a slightly stronger profit outlook and updated P/E assumptions. At the same time, they have tempered revenue growth expectations and applied a modestly higher discount rate.내러티브 업데이트 • Apr 20
SRTA: Bullish Execution On Raised 2026 Revenue Outlook May Unlock Future Upside
The Analyst Price Target for Strata Critical Medical has been revised from $9.63 to $8.81, with analysts pointing to updated assumptions on revenue growth, profit margins, and a higher forward P/E multiple, despite generally bullish recent coverage. Analyst Commentary Recent research coverage on Strata Critical Medical has been largely constructive, with analysts updating their models to reflect revised assumptions on revenue, margins, and valuation multiples.내러티브 업데이트 • Apr 06
SRTA: Raised Revenue Outlook And Richer Future P/E Will Support Upside
Analysts have raised their price target on Strata Critical Medical to $8.00 per share, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, supported by recent bullish initiation reports from multiple firms. Analyst Commentary Recent bullish initiation reports on Strata Critical Medical highlight constructive views on the company’s long term prospects, but not all commentary is aligned with that optimism.내러티브 업데이트 • Mar 23
SRTA: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their price target on Strata Critical Medical to $8.00. This reflects updated assumptions for significantly higher revenue growth, lower profit margins, and a substantially higher future P/E multiple.내러티브 업데이트 • Mar 09
SRTA: Higher Revenue Outlook And Impairment Charge Will Support Future Upside
Analysts have adjusted their price target on Strata Critical Medical to $9.63, reflecting updated assumptions that combine a different discount rate and future P/E with materially higher modeled revenue growth and slightly lower profit margins. What's in the News Strata Critical Medical raised its 2026 revenue guidance to a range of $260 million to $275 million, compared with the prior range of $255 million to $270 million (Key Developments).내러티브 업데이트 • Feb 22
SRTA: Higher Margin Outlook Will Support Future Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00, reflecting updated assumptions for slightly higher revenue, improved profit margins, a modestly higher discount rate, and a lower future P/E multiple. Valuation Changes Fair Value: $8.00 stays unchanged, with the revised assumptions still pointing to the same central estimate.내러티브 업데이트 • Feb 07
SRTA: Higher Margins And Updated Guidance Will Support Stronger Future Returns
Analysts have modestly reset their price target for Strata Critical Medical to $11.25, citing updated assumptions around slightly higher revenue growth, tighter profit margins at 18.60% and a lower future P/E of about 25.74x as key drivers of the revised view. What's in the News Strata Critical Medical issued earnings guidance for 2026, expecting revenue between $255 million and $270 million.내러티브 업데이트 • Jan 24
SRTA: Higher Margin Outlook And Revenue Guidance Will Support Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00. The updated view reflects slightly different assumptions around revenue growth, profit margin and future P/E that they see as better aligning with their current outlook for the business.내러티브 업데이트 • Jan 09
SRTA: Higher Margin Outlook Will Drive Stronger Earnings Power Ahead
Analysts have raised their fair value estimate for Strata Critical Medical from $5.00 to $8.00, citing updated assumptions that include a lower discount rate, a revised outlook for revenue growth, higher expected profit margins, and a reduced future P/E multiple. What's in the News Strata Critical Medical issued earnings guidance for 2026, with expected revenue in a range of $255 million to $270 million.분석 기사 • Jan 06
Strata Critical Medical, Inc.'s (NASDAQ:SRTA) 30% Price Boost Is Out Of Tune With Revenues
Strata Critical Medical, Inc. ( NASDAQ:SRTA ) shares have had a really impressive month, gaining 30% after a shaky...내러티브 업데이트 • Dec 17
SRTA: Lower Risk Profile And Rising Margins Will Drive Stronger Future Returns
Analysts have raised their price target for Strata Critical Medical from 6.50 dollars to 11.25 dollars, citing a lower perceived risk profile and materially stronger long term profitability expectations, despite moderating revenue growth assumptions and a slightly lower future P E multiple. What's in the News Strata Critical Medical issued 2026 revenue guidance, forecasting between 255 million dollars and 270 million dollars.내러티브 업데이트 • Dec 03
SRTA: Keystone Acquisition Will Drive Expanded Cash Deployment And Future Earnings Upside
Analysts have nudged their price target on Strata Critical Medical higher to $9.63 from $9.25, citing the strategically accretive Keystone Perfusion Services acquisition and the company’s more constructive growth outlook as key drivers. Analyst Commentary Bullish analysts view the Keystone Perfusion Services acquisition as a strategically important use of Strata Critical Medical's sizable cash balance.내러티브 업데이트 • Nov 19
SRTA: Keystone Acquisition Will Drive Material Revenue Expansion And Lower Risk
Analysts have raised their price target for Strata Critical Medical to $7.25, up from $6.50. They cite strong support for the company's recent acquisition of Keystone Perfusion Services as a strategic use of its significant cash reserves.내러티브 업데이트 • Nov 03
SRTA: Cash Deployment Through Acquisition Will Drive Expansion In Healthcare Reach
Analysts have raised their price target for Strata Critical Medical to $9.25, up from $7.83. They cited stronger strategic deployment of cash resources with the acquisition of Keystone Perfusion Services and improved expectations for future performance.내러티브 업데이트 • Sep 23
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
Strata Critical Medical’s consensus price target has risen from $5.83 to $7.83, as analysts express increased confidence in management’s ability to deploy capital efficiently and drive shareholder value following the accretive acquisition of Keystone Perfusion Services. Analyst Commentary Bullish analysts highlight the successful deployment of Strata's large $235M pro forma cash position through the acquisition of Keystone Perfusion Services for $124M.내러티브 업데이트 • Aug 06
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
The consensus analyst price target for Blade Air Mobility has increased, primarily driven by higher revenue growth forecasts and a rising future P/E, bringing the fair value estimate up from $7.20 to $7.75. What's in the News Joby Aviation is exploring an acquisition of Blade Air Mobility to access a ready customer base for electric air taxis; no final decision has been made.분석 기사 • May 15
Earnings Release: Here's Why Analysts Cut Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Price Target To US$7.20
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) investors will be delighted, with the company turning in some strong numbers...분석 기사 • May 13
Blade Air Mobility, Inc. (NASDAQ:BLDE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Those holding Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares would be relieved that the share price has rebounded 29...
새로운 내러티브 • Mar 31
eVTOL And Urban Air Mobility Will Open New Routes
Transition to electric vertical aircraft (eVTOL) promises long-term growth by enabling new routes and attracting a wider customer base.Seeking Alpha • Feb 26
Blade Air Mobility: Organ Transport Growth Now, eVTOL Growth Later
Summary Blade currently focuses on organ transport and passenger transport. The company is expanding in the organ logistics market. New perfusion technologies and competition provide a risk to the business. Air taxi services using eVTOLs provide a margin expansion opportunity. The stock is a speculative buy at this point. Read the full article on Seeking Alpha분석 기사 • Nov 30
Revenues Not Telling The Story For Blade Air Mobility, Inc. (NASDAQ:BLDE) After Shares Rise 27%
Despite an already strong run, Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares have been powering on, with a gain of...Seeking Alpha • Nov 18
Blade: Transition To Profitability Should Provide Support Going Forward
Summary Blade's growth was weak in Q3, largely due to the company abandoning activities with marginal economics. Policy reforms and new technologies are driving growth in transplant volumes and transportation distances but competition is likely to increase in coming quarters. Provided Blade's margins continue to improve, the stock should move higher at some point. This will likely require an improvement in growth though. eVTOLs should provide Blade's passenger segment with a significant boost but this remains several years away. Read the full article on Seeking Alpha분석 기사 • Nov 15
Analysts Have Made A Financial Statement On Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Third-Quarter Report
Last week, you might have seen that Blade Air Mobility, Inc. ( NASDAQ:BLDE ) released its third-quarter result to the...분석 기사 • Sep 16
Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Business Is Trailing The Industry But Its Shares Aren't
When you see that almost half of the companies in the Airlines industry in the United States have price-to-sales ratios...Seeking Alpha • Aug 15
Blade: Margins Remain An Issue
Summary Blade Air Mobility, Inc.'s business continues to expand, but revenue growth is being dampened by the company's decision to discontinue unprofitable activities. Competition from TransMedics poses a threat, and this issue is likely to come to a head in coming quarters. While Blade has managed to reduce its losses, stock-based compensation is causing fairly significant dilution. Blade's low valuation could be an opportunity, but the company probably needs to stabilize its growth and address dilution before the stock moves higher. Read the full article on Seeking Alpha분석 기사 • Jun 19
Here's Why We're Not At All Concerned With Blade Air Mobility's (NASDAQ:BLDE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • May 16
Blade Air Mobility: No Signs Of Competition Yet
Summary Rising organ transportation competition poses a threat to Blade's Medical segment, but Q1 revenue suggests there hasn't been a material impact so far. TransMedics' strong logistics growth and aggressive expansion plan put Blade and TransMedics on a collision course in coming years. Blade's valuation is low though, and if the Medical segment continues to grow or eVTOLs expand the UAM market, the stock could perform well. Read the full article on Seeking Alpha분석 기사 • May 10
Analysts Are Updating Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Estimates After Its First-Quarter Results
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) defied analyst predictions to release its first-quarter results, which were...주주 수익률
| SRTA | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 8.3% | -2.4% | 1.4% |
| 1Y | 56.8% | 17.6% | 25.7% |
수익률 대 산업: SRTA은 지난 1년 동안 17.6%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: SRTA은 지난 1년 동안 25.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| SRTA volatility | |
|---|---|
| SRTA Average Weekly Movement | 7.6% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: SRTA는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: SRTA의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2014 | 327 | Melissa Tomkiel | www.stratacritical.com |
는 미국 의료 업계에 시간 관리가 중요한 물류 및 의료 서비스를 제공합니다. 이 회사는 물류와 임상의 두 부문으로 운영됩니다. 이 회사는 인체 장기, 이식 팀, 관련 의료 자재 및 장기 배치 서비스를 위한 항공 및 지상 운송과 같은 물류 서비스와 장기 회수 절차, 정상 체온 국소 관류 및 보존 서비스를 포함한 이식 임상 서비스를 제공합니다.
Strata Critical Medical, Inc. 기초 지표 요약
| SRTA 기초 통계 | |
|---|---|
| 시가총액 | US$508.78m |
| 순이익 (TTM) | -US$16.05m |
| 매출 (TTM) | US$228.58m |
2.2x
주가매출비율(P/S)-31.7x
주가수익비율(P/E)SRTA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SRTA 손익계산서 (TTM) | |
|---|---|
| 매출 | US$228.58m |
| 매출원가 | US$180.39m |
| 총이익 | US$48.19m |
| 기타 비용 | US$64.24m |
| 순이익 | -US$16.05m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.19 |
| 총이익률 | 21.08% |
| 순이익률 | -7.02% |
| 부채/자본 비율 | 0% |
SRTA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/20 23:18 |
| 종가 | 2026/06/18 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Strata Critical Medical, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Itay Michaeli | Citigroup Inc |
| William Bonello | Craig-Hallum Capital Group LLC |